Glenmark receives ANDA approval for triamcinolone acetonide cream

It is the generic version of Delcor Asset Corporation’s Kenalog cream

Glenmark Pharmaceuticals, US has been granted final approval by the United States Food & Drug Administration (US FDA) for triamcinolone acetonide cream USP, 0.1 per cent, the generic version of Kenalog Cream, 0.1 per cent of Delcor Asset Corporation (which is no longer being marketed in the US).

According to IMS Health sales data for the 12 month period ending June 2016, the Kenalog cream, 0.1 per cent market achieved annual sales of approximately $43.6 million.

Glenmark’s current portfolio consists of 108 products authorised for distribution in the US marketplace and 61 ANDAs pending approval with the US FDA.